β(2) -adrenoceptor agonists: current and future direction (Q24604047)

British Journal of Pharmacology

Europe PubMed Central

title

β(2) -adrenoceptor agonists: current and future direction (English)

0 references

author name string

Mario Cazzola

series ordinal

1

0 references

Luigino Calzetta

series ordinal

2

0 references

Maria Gabriella Matera

series ordinal

3

0 references

language of work or name

English

0 references

publication date

May 2011

0 references

published in

0 references

volume

163

0 references

issue

1

0 references

page(s)

4-17

0 references

cites work

Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Indacaterol: in chronic obstructive pulmonary disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Indacaterol for chronic obstructive pulmonary disease (COPD).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Novel bronchodilators in asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Emerging inhaled bronchodilators: an update

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Safety of long-acting beta2-agonists in the treatment of asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

The risk of asthma mortality with inhaled long acting beta-agonists

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Novel long-acting bronchodilators for COPD and asthma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Global strategy for asthma management and prevention: GINA executive summary.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Adherence to Prescribed Treatment for Asthma: Evidence from Pharmacy Benefits Data

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Overcoming barriers to nonadherence in asthma treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

The beta-agonist controversy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Functional antagonism: tolerance produced by inhaled beta 2 agonists

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

The use of bronchodilators in stable chronic obstructive pulmonary disease.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Carbostyril-based beta-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action

30 May 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Asthma Mortality and Long-Acting Beta2-Agonists in Five Major European Countries, 1994–2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085864

Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma

28 November 2018

1 reference

12 December 2020

Beta-adrenergic modulation of human type-1/type-2 cytokine balance

1 reference

12 December 2020

Tracheal Relaxing Effects and β2-Selectivity of TA-2005, a Newly Developed Bronchodilating Agent, in Isolated Guinea Pig Tissues

1 reference

12 December 2020

TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists

1 reference

12 December 2020

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

12 December 2020

The FDA and safe use of long-acting beta-agonists in the treatment of asthma

1 reference

12 December 2020

Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD

1 reference

12 December 2020

A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005

1 reference

12 December 2020

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

12 December 2020

The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005

1 reference

12 December 2020

Dual-acting beta2 agonists/muscarinic antagonists

1 reference

12 December 2020

The beta-agonist saga and its clinical relevance: on and on it goes

1 reference

12 December 2020

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5381.2011.01216.X

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1111/J.1476-5381.2011.01216.X

1 reference

1 reference

1 reference

PubMed publication ID

21232045

1 reference